 Complement C1 Inhibitor Protein
"Complement C1 Inhibitor Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES. It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES I AND II.
| Descriptor ID |
D050718
|
| MeSH Number(s) |
D12.644.822.750.140.500 D12.644.861.140.500 D12.776.124.486.274.920.250.500 D12.776.395.320 D12.776.645.750.140.500 D12.776.872.140.500
|
| Concept/Terms |
Complement C1 Inhibitor Protein- Complement C1 Inhibitor Protein
- Serpin G1
- G1, Serpin
- Complement C1-Inhibitor Protein
- C1-INH Protein
- C1 INH Protein
- C1-Inhibitor Protein
- C1 Inhibitor Protein
- Plasma Protease C1 Inhibitor
- C1 Esterase Inhibitor
- Esterase Inhibitor, C1
|
Below are MeSH descriptors whose meaning is more general than "Complement C1 Inhibitor Protein".
Below are MeSH descriptors whose meaning is more specific than "Complement C1 Inhibitor Protein".
This graph shows the total number of publications written about "Complement C1 Inhibitor Protein" by people in this website by year, and whether "Complement C1 Inhibitor Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 3 | 0 | 3 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement C1 Inhibitor Protein" by people in Profiles.
-
Jacobs J, Neeno T. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency. Postgrad Med. 2021 Aug; 133(6):639-650.
-
Craig T, Zuraw B, Longhurst H, Cicardi M, Bork K, Grattan C, Katelaris C, Sussman G, Keith PK, Yang W, Hébert J, Hanzlikova J, Staubach-Renz P, Martinez-Saguer I, Magerl M, Aygören-Pürsün E, Farkas H, Reshef A, Kivity S, Neri S, Crisan I, Caballero T, Baeza ML, Hernandez MD, Li H, Lumry W, Bernstein JA, Hussain I, Anderson J, Schwartz LB, Jacobs J, Manning M, Levy D, Riedl M, Christiansen S, Feuersenger H, Pragst I, Mycroft S, Pawaskar D, Jacobs I. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. J Allergy Clin Immunol Pract. 2019 Jul - Aug; 7(6):1793-1802.e2.
-
Lumry WR, Martinez-Saguer I, Yang WH, Bernstein JA, Jacobs J, Moldovan D, Riedl MA, Johnston DT, Li HH, Tang Y, Schranz J, Lu P, Vardi M, Farkas H. Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1610-1618.e4.
-
Craig T, Lumry W, Cicardi M, Zuraw B, Bernstein JA, Anderson J, Jacobs J, Riedl MA, Manning ME, Banerji A, Gower RG, Caballero T, Farkas H, Feuersenger H, Jacobs I, Machnig T, Longhurst H. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. J Allergy Clin Immunol Pract. 2019 Jul - Aug; 7(6):2035-2038.
-
Pawaskar D, Tortorici MA, Zuraw B, Craig T, Cicardi M, Longhurst H, Li HH, Lumry WR, Martinez-Saguer I, Jacobs J, Bernstein JA, Riedl MA, Katelaris CH, Keith PK, Feussner A, Sidhu J. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema. Clin Exp Allergy. 2018 10; 48(10):1325-1332.
-
Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, Li HH, Reshef A, Bonner J, Bernstein JA, Anderson J, Lumry WR, Farkas H, Katelaris CH, Sussman GL, Jacobs J, Riedl M, Manning ME, Hebert J, Keith PK, Kivity S, Neri S, Levy DS, Baeza ML, Nathan R, Schwartz LB, Caballero T, Yang W, Crisan I, Hernandez MD, Hussain I, Tarzi M, Ritchie B, Králícková P, Guilarte M, Rehman SM, Banerji A, Gower RG, Bensen-Kennedy D, Edelman J, Feuersenger H, Lawo JP, Machnig T, Pawaskar D, Pragst I, Zuraw BL. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med. 2017 03 23; 376(12):1131-1140.
-
Jacobs J. Recurrent attacks of hereditary angioedema: a case of delayed diagnosis. Allergy Asthma Proc. 2011 Sep-Oct; 32 Suppl 1:23-26.
-
Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, Craig T, Grant JA, Hurewitz D, Bielory L, Cartwright WE, Koleilat M, Ryan W, Schaefer O, Manning M, Patel P, Bernstein JA, Friedman RA, Wilkinson R, Tanner D, Kohler G, Gunther G, Levy R, McClellan J, Redhead J, Guss D, Heyman E, Blumenstein BA, Kalfus I, Frank MM. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010 Aug 05; 363(6):513-22.
-
Craig T, Riedl M, Dykewicz MS, Gower RG, Baker J, Edelman FJ, Hurewitz D, Jacobs J, Kalfus I. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol. 2009 May; 102(5):366-72.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|